D. E. Shaw & Co., Inc. Rapt Therapeutics, Inc. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $100 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding RAPT
# of Institutions
95Shares Held
111MCall Options Held
41.3KPut Options Held
100-
Orbimed Advisors LLC San Diego, CA13.1MShares$134 Million0.5% of portfolio
-
Tcg Crossover Management, LLC Palo Alto, CA13.1MShares$134 Million3.85% of portfolio
-
Foresite Capital Management Vi LLC Larkspur, CA12.5MShares$128 Million8.35% of portfolio
-
Rtw Investments, LP New York, NY11.8MShares$120 Million0.24% of portfolio
-
Bvf Inc San Francisco, CA9.24MShares$94.5 Million0.5% of portfolio
About RAPT Therapeutics, Inc.
- Ticker RAPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 29,656,600
- Market Cap $303M
- Description
- RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...